Mangrove Partners IM LLC Purchases New Position in Molina Healthcare, Inc $MOH

Mangrove Partners IM LLC acquired a new position in Molina Healthcare, Inc (NYSE:MOH) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,252 shares of the company’s stock, valued at approximately $814,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MOH. Bogart Wealth LLC acquired a new stake in Molina Healthcare in the third quarter valued at approximately $39,000. CYBER HORNET ETFs LLC acquired a new position in shares of Molina Healthcare during the 2nd quarter worth $45,000. SJS Investment Consulting Inc. raised its holdings in shares of Molina Healthcare by 6,225.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 253 shares of the company’s stock valued at $48,000 after purchasing an additional 249 shares in the last quarter. MUFG Securities EMEA plc bought a new position in shares of Molina Healthcare during the 2nd quarter valued at $48,000. Finally, Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of Molina Healthcare in the 3rd quarter valued at $50,000. Institutional investors own 98.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on MOH. Wells Fargo & Company set a $141.00 price objective on shares of Molina Healthcare and gave the stock an “equal weight” rating in a report on Friday, February 20th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Molina Healthcare in a research report on Thursday, January 22nd. Cantor Fitzgerald decreased their price target on Molina Healthcare from $180.00 to $144.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Truist Financial decreased their price target on Molina Healthcare from $190.00 to $145.00 and set a “hold” rating for the company in a research note on Tuesday, February 17th. Finally, Mizuho cut their price objective on Molina Healthcare from $220.00 to $180.00 and set an “outperform” rating on the stock in a research note on Thursday. Two research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Molina Healthcare currently has an average rating of “Hold” and an average price target of $169.21.

Molina Healthcare Stock Performance

NYSE:MOH opened at $149.08 on Friday. The firm’s 50-day moving average is $163.64 and its 200-day moving average is $167.17. The company has a market cap of $7.68 billion, a price-to-earnings ratio of 17.42 and a beta of 0.52. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.69 and a current ratio of 1.69. Molina Healthcare, Inc has a 52-week low of $121.06 and a 52-week high of $359.97.

Molina Healthcare (NYSE:MOH) last released its earnings results on Thursday, February 5th. The company reported ($2.75) earnings per share for the quarter, missing the consensus estimate of $0.43 by ($3.18). Molina Healthcare had a net margin of 1.04% and a return on equity of 13.60%. The company had revenue of $11.38 billion during the quarter, compared to the consensus estimate of $10.90 billion. During the same quarter in the previous year, the business posted $5.05 EPS. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. Molina Healthcare has set its FY 2026 guidance at 5.000- EPS. Equities research analysts anticipate that Molina Healthcare, Inc will post 24.4 earnings per share for the current year.

About Molina Healthcare

Molina Healthcare, Inc is a managed care company specializing in government-sponsored health insurance programs. The company offers Medicaid managed care plans, Medicare Advantage and prescription drug plans, and individual Marketplace plans under the Affordable Care Act. Through an integrated care model, Molina emphasizes preventive and primary care services, care coordination, and disease management to improve health outcomes for its members.

The company traces its roots to the early 1980s, when Dr.